Pharmagen (PHRX)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Jan 31, 2024 03:28 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
PHRX 0.00 0.00(0.00%)
Will PHRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PHRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for PHRX
PharmaDrug Welcomes New Board Member
PharmaDrug Advances with PD-001 Clinical Trials
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
PharmaDrug Innovates in Biosynthetic Cocaine Production
PharmaDrug Inc’s Innovative Cocaine Supply Solution